Skip to main content
. 2019 Nov 1;19:194. doi: 10.1186/s12890-019-0969-5

Table 2.

Clinical characteristics of patients with MPO-ANCA nephritis with a UIP pattern and patients with IPF

Characteristics MPO-ANCA nephritis with UIP pattern IPF p-value
Patients 31 32
Age, years 74 (58–88) 70 (58–87) 0.083
Male 16 29 0.0021
Smoking history
 Never/former or current 16/15 6/26 0.0068
Respiratory symptoms
 Cough 19 16 0.37
 Dyspnea 12 18 0.16
 None 9 6 0.34
Serological testing
 LDH, U/L 225.5 ± 64.9 236.2 ± 45.1 0.35
 KL-6, IU/mL 1298 ± 914.8 1341 ± 853.5 0.73
Treatment
 None 2 (6.5) 0 (0.0)
 Immunosuppressive agents 28 (90.0) 0 (0.0)
 Antifibrotic agents 1 (3.2) 32 (100.0)
nintedanib nintedanib n = 14
300 mg/day 300 mg/day n = 4
200 mg/day n = 10
pirfenidone n = 18
1800 mg/day n = 3
1200 mg/day n = 11
600 mg/day n = 4

Data are presented as n, median (range), mean ± standard deviation, or n (%)

MPO-ANCA nephritis myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis, UIP usual interstitial pneumonia, IPF idiopathic pulmonary fibrosis, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6